When all is said and done, what you'll probably see is some sort of negotiated settlement here, whether it's a breakup fee, or lower purchase price. Neither company has a strong interest in seeing this resolved in the court.

Neither company has a strong interest in seeing this resolved in the court.

It's very clear Boston Scientific is not making this acquisition for what this company can do in 2006, 2007. This is a long-term strategic acquisition for them.

When we look back in three years, there's going to be a higher likelihood that those companies that repatriated substantial non-U.S. profits have done major transactions compared with companies that have not repatriated assets.

I have to believe, given the level of discussion I've heard about it, that bankers are certainly out there identifying companies that are repatriating large sums and doing what they can to get their business.

When all is said and done, what you'll probably see is some sort of negotiated settlement here, whether it's a breakup fee, or lower purchase price.